Navigation Links
/CORRECTION//- RxElite Temporarily Suspends Sales Under Its Registration Statement
Date:1/8/2008

MERIDIAN, Idaho, Jan. 8 /PRNewswire-FirstCall/ -- RxElite, Inc. (OTC Bulletin Board: RXEI), a developer, manufacturer, and marketer of specialty generic prescription drug products, announced today that as permitted under the registration rights agreement, it has voluntarily instructed all named selling stockholders to cease using the company's Registration Statement on Form SB-2 (File No. 333-146641) and January 3, 2008 prospectus until further advised. This release corrects and should replace the release of January 4, 2008 in its entirety. Once conditions permit reliance on the prospectus included in the Registration Statement, the company will notify selling stockholders.

This notice is provided for informational purposes only, and does not represent a solicitation or offer to buy or sell any security. Any offer will be made my means of a current prospectus only. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sales of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About RxElite, Inc.

RxElite, Inc. develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs), and transdermal patch products.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving known and unknown risks, delays, and uncertainties that may cause our actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks, delays, and uncertainties include, but are not lim
'/>"/>

SOURCE RxElite, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection
2. Surgical and Trauma Wound Care Market to Tie Up $7 Billion in Sales by 2011
3. ForceLogix, Innovex Win Sales Operational Performance Award
4. Southern Research Expands Sales and Marketing Agreement with Absorption Systems to Service European Market
5. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
6. Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin
7. Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54.
8. OmniSonics Appoints Sean McNerney as Vice President, Sales
9. SPO Medical Announces Major Sales Milestone
10. Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011
11. Stallergenes : 3rd Quarter Sales Up 17%: 9- Month Cumulative Sales Up 17%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 Becht Engineering Co., Inc., ... has acquired The CECON Group, Inc., located in ... not announced. , Becht Engineering (http://www.becht.com ) ... including oil and gas production, refining, petrochemical, chemical, ... power sectors. The company has twelve offices in ...
(Date:3/3/2015)... DUBLIN , Mar. 03, 2015 Research ... announced the addition of Jain PharmaBiotech,s new report ... to their offering. , ... is to match the right drug to the ... design the appropriate treatment for a patient according ...
(Date:3/3/2015)... 2015  Johnson & Johnson Innovation LLC today announced ... (JLABS @SSF), a 30,000-square foot incubator located ... Francisco, Calif. The Johnson & Johnson Innovation, ... from across the healthcare spectrum including biotech, pharmaceutical, medical ... first resident startups have been selected, including the winners ...
(Date:3/3/2015)... ROCKVILLE, Md. , March 3, 2015  Synthetic Biologics, ... serious infections and diseases, with a focus on protecting the ... Officer, is scheduled to present at the 27th Annual ROTH ... Laguna Niguel in Dana ... on Tuesday, March 10, 2015 at 1:00 p.m. (Pacific Time). ...
Breaking Biology Technology:Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 2Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 2Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 4Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 5Synthetic Biologics to Present at the 27th Annual ROTH Conference 2
... new USP 797,regulations, which become effective June 1st, ... minimums has the potential of creating new,hazards for ... Microtest, Inc., Issued by the U.S. Pharmacopoeia, ... sampling and testing as a minimum,requirement, in place ...
... Initiate Phase II Trial for IPLEX(TM) in Retinopathy ... Sept. 23 ,Insmed Inc. (Nasdaq CM: INSM), a ... AB, a biopharmaceutical company,dedicated to the development of ... premature birth, today noted the presentation of,clinical study ...
... Phase 4 Study Initiated Pre-Registration,-, COLLEGEVILLE, Pa., ... (NYSE: WYE ), today announced the initiation ... a major study in,adults of an investigational 13-valent ... the leading cause of bacterial pneumonia,in adults., ...
Cached Biology Technology:New USP 797 Regulations May Create New Hazards for Compounding Pharmacy Directors 2New USP 797 Regulations May Create New Hazards for Compounding Pharmacy Directors 3Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants 2Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants 3Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants 4Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants 5Major Adult Vaccine Clinical Trial for Pneumonia Prevention Begins 2Major Adult Vaccine Clinical Trial for Pneumonia Prevention Begins 3Major Adult Vaccine Clinical Trial for Pneumonia Prevention Begins 4Major Adult Vaccine Clinical Trial for Pneumonia Prevention Begins 5
(Date:2/23/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... for DISTRIBUTED VOICE DIRECTED PAYMENT METHOD AND ... new groundbreaking payment method. Payment accounts may be selected ... be accessed if both the speech (the word associated ...
(Date:2/12/2015)... Feb. 12, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... patent 62/113114 for DISTRIBUTED METHOD AND SYSTEM ... The patent further establishes NXT-ID,s position in the emerging ... portfolio the ability for multiple devices to collaborate with ...
(Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2
... College of Georgia nurse researcher is among the first in ... through the American Recovery and Reinvestment Act of 2009. ... and the research of African-Americans in the Augusta community who ... to create or save more than 3.5 million jobs over ...
... Darwin described the sudden origin of flowering plants about 130 ... have yet to solve. But a new University ... online edition of the Proceedings of the National Academy ... with information about what the first flowers looked like and ...
... key to Komodo Dragon,s hunting strategy. A new ... Dragon bite is a combination of highly specialized serrated ... accepted theory that prey die from septicemia caused by ... sophisticated medical imaging techniques, an international team led by ...
Cached Biology News:MCG researcher among first to receive NIH stimulus funding 2University of Florida study provides insight into evolution of first flowers 2University of Florida study provides insight into evolution of first flowers 3A combined tooth-venom arsenal revealed as key to Komodo dragon's hunting strategy 2